News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
496,762 Results
Type
Article (9990)
Company Profile (157)
Press Release (486702)
Multimedia
Podcasts (16)
Webinars (7)
Section
Business (171513)
Career Advice (367)
Deals (26376)
Drug Delivery (15)
Drug Development (54279)
Employer Resources (22)
FDA (9943)
Job Trends (8967)
News (244353)
Policy (18384)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (592)
Accelerated approval (21)
ADA (21)
Adcomms (1)
Allergies (98)
Alliances (34457)
ALS (106)
Alzheimer's disease (1002)
Antibody-drug conjugate (ADC) (292)
Approvals (10518)
Artificial intelligence (346)
ASCO (169)
Autoimmune disease (207)
Automation (32)
Bankruptcy (269)
Best Places to Work (7161)
BIO (41)
BIOSECURE Act (3)
Biosimilars (123)
Biotechnology (99)
Bladder cancer (136)
Brain cancer (33)
Breast cancer (514)
Cancer (3746)
Cardiovascular disease (224)
Career advice (297)
Career pathing (2)
CAR-T (183)
CDC (2)
Celiac Disease (1)
Cell therapy (516)
Cervical cancer (40)
Clinical research (48793)
Collaboration (1333)
Commercialization (1)
Company closure (3)
Compensation (1408)
Complete response letters (36)
COVID-19 (889)
CRISPR (69)
C-suite (793)
Cystic fibrosis (89)
Data (5683)
Denatured (10)
Depression (109)
Dermatology (61)
Diabetes (350)
Diagnostics (4306)
Digital health (36)
Diversity (2)
Diversity, equity & inclusion (4)
Drug discovery (178)
Drug pricing (16)
Drug shortages (2)
Duchenne muscular dystrophy (179)
Earnings (73872)
Editorial (6)
Employer branding (3)
Employer resources (20)
Events (89221)
Executive appointments (741)
FDA (12531)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (17)
Frontotemporal dementia (23)
Funding (1028)
Gene editing (142)
Generative AI (12)
Gene therapy (352)
GLP-1 (344)
Government (1065)
Grass and pollen (2)
Guidances (285)
Healthcare (9607)
Hematology (95)
HIV (54)
Huntington's disease (24)
IgA nephropathy (63)
Immunology and inflammation (132)
Immuno-oncology (68)
Indications (154)
Infectious disease (1091)
Inflammatory bowel disease (134)
Inflation Reduction Act (8)
Influenza (88)
Intellectual property (255)
Interviews (48)
IPO (12604)
IRA (7)
Job creations (2141)
Job search strategy (282)
JPM (5)
Kidney cancer (19)
Labor market (13)
Layoffs (105)
Leadership (3)
Legal (5294)
Liver cancer (47)
Longevity (18)
Lung cancer (511)
Lymphoma (250)
Machine learning (30)
Management (7)
Manufacturing (553)
Marketing (7)
MASH (120)
Medical device (8779)
Medtech (8905)
Mergers & acquisitions (14790)
Metabolic disorders (739)
mRNA (61)
Multiple sclerosis (106)
NASH (4)
Neurodegenerative disease (233)
Neuropsychiatric disorders (47)
Neuroscience (1885)
NextGen: Class of 2026 (3354)
Non-profit (974)
Now hiring (15)
Obesity (245)
Opinion (31)
Ovarian cancer (159)
Pain (175)
Pancreatic cancer (207)
Parkinson's disease (206)
Partnered (14)
Patents (473)
Patient recruitment (496)
Peanut (32)
People (42831)
Pharmaceutical (31)
Pharmacy benefit managers (8)
Phase 1 (15898)
Phase 2 (21854)
Phase 3 (14739)
Pipeline (6914)
Policy (33)
Postmarket research (1582)
Preclinical (6724)
Press Release (34)
Prostate cancer (192)
Psychedelics (12)
Radiopharmaceuticals (196)
Rare diseases (607)
Real estate (3261)
Recruiting (10)
Regulatory (15128)
Reports (20)
Research institute (685)
Resumes & cover letters (53)
Rett syndrome (39)
RNA editing (8)
RSV (49)
Schizophrenia (108)
Series A (186)
Series B (137)
Service/supplier (4)
Sickle cell disease (65)
Special edition (3)
Spinal muscular atrophy (88)
Sponsored (6)
Startups (2287)
Stomach cancer (5)
Supply chain (51)
Tariffs (2)
The Weekly (6)
Vaccines (355)
Venture capital (36)
Weight loss (94)
Women's health (79)
Worklife (1)
Date
Today (73)
Last 7 days (296)
Last 30 days (1171)
Last 365 days (19902)
2026 (11301)
2025 (20052)
2024 (23690)
2023 (27298)
2022 (35638)
2021 (38310)
2020 (34604)
2019 (24155)
2018 (18249)
2017 (19422)
2016 (18576)
2015 (24871)
2014 (22093)
2013 (18611)
2012 (20716)
2011 (20885)
2010 (20722)
Location
Africa (251)
Alabama (74)
Alaska (2)
Arizona (299)
Arkansas (12)
Asia (19026)
Australia (2294)
California (11869)
Canada (3101)
China (566)
Colorado (474)
Connecticut (401)
Delaware (207)
Europe (27467)
Florida (1736)
Georgia (365)
Hawaii (4)
Idaho (47)
Illinois (706)
India (44)
Indiana (318)
Iowa (13)
Japan (394)
Kansas (108)
Kentucky (31)
Louisiana (26)
Maine (25)
Maryland (1179)
Massachusetts (7810)
Michigan (306)
Minnesota (551)
Mississippi (5)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (113)
New Hampshire (64)
New Jersey (2592)
New Mexico (12)
New York (2763)
North Carolina (1257)
North Dakota (4)
Northern California (5934)
Ohio (283)
Oklahoma (15)
Oregon (19)
Pennsylvania (2219)
Puerto Rico (21)
Rhode Island (31)
South America (425)
South Carolina (75)
South Dakota (1)
Southern California (4881)
Tennessee (121)
Texas (1907)
United States (38452)
Utah (351)
Vermont (1)
Virginia (153)
Washington D.C. (41)
Washington State (950)
West Virginia (2)
Wisconsin (84)
496,762 Results for "asc biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
July 5, 2026
·
5 min read
Press Releases
OrthAlign, Inc. Receives FDA 510(k) clearance for the Lantern® ASC system
June 3, 2026
·
3 min read
Press Releases
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
June 8, 2026
·
6 min read
Press Releases
Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
July 15, 2026
·
4 min read
Press Releases
Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care
July 21, 2026
·
6 min read
Press Releases
Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
July 27, 2026
·
4 min read
Press Releases
Resverlogix Corp. Announces Issuance of MCTO by ASC
April 2, 2026
·
4 min read
Press Releases
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
July 23, 2026
·
3 min read
Press Releases
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
April 7, 2026
·
4 min read
Mergers & acquisitions
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
The star of the takeover is Forte Biosciences’ investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
July 27, 2026
·
2 min read
·
Tristan Manalac
1 of 49,677
Next
